

IN THE CLAIMS

Please amend claims 15-18, and 22-27, cancel claims 11-14, 19-22 and 28-37,
and add new claims 38-41 as follow:

1-20
Ex. note

1-14. (Cancelled)

15. (Currently amended) A The vaccine formulation suitable for mucosal administration according to claim 11, wherein the surface antigen comprising:
(a) a mixture of a first vaccine antigen which is Hepatitis B virus surface antigen (HBsAg), and the
(b) a second vaccine antigen which is an antigen of a viral nucleocapsid; wherein said HBsAg has an adjuvant effect on the second vaccine antigen, and wherein said first and second vaccine antigens are each present from 0.001mg to 1mg.

③
contd.

16. (Currently amended) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is a virus-like particle comprising the nucleocapsid antigen of Hepatitis B virus.

17. (Currently amended) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is a virus-like particle comprising the nucleocapsid antigen of Human Papilloma virus (HPV).

18. (Currently amended) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is a virus-like particle comprising the nucleocapsid antigen of Hepatitis C virus.

19-20. (Cancelled)

21. (Previously amended) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for nasal administration.

22. (Currently amended) The vaccine formulation according to claim ~~11~~ 15, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis B virus (HBV) infection.
23. (Currently amended) The vaccine formulation according to claim ~~11~~ 15, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis B virus (HBV) infection.
24. (Currently amended) The vaccine formulation according to claim ~~11~~ 18, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis C virus (HCV) infection.
25. (Currently amended) The vaccine formulation according to claim ~~11~~ 17, wherein the vaccine formulation is suitable for use as a preventive vaccine against Human Papilloma virus (HPV) infection.
26. (Currently amended) The vaccine formulation according to claim ~~11~~ 18, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis C virus (HCV) infection.
27. (Currently amended) The vaccine formulation according to claim ~~11~~ 17, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Human Papilloma virus (HPV) infection.
- 28-37. (Cancelled)
28. (New) A vaccine formulation suitable for mucosal administration, comprising:
- (a) a mixture of a first vaccine antigen which is Hepatitis B virus surface antigen (HBsAg), and
 - (b) a second vaccine antigen and a third vaccine antigen, wherein vaccine antigens are each present from 0.001mg to 1mg.
39. (New) The vaccine formulation according to claim 38, wherein the second vaccine antigen is an antigen of a viral nucleocapsid.
- 03

Application No. 09/857,402

Filing Date: June 1, 2001

Docket: 976-11 PCT/US

Page 5 of 17

40. (New) The vaccine formulation according to claim 39, wherein the viral nucleocapsid is the nucleocapsid antigen of Human Papilloma Virus (HPV).

41. (New) The vaccine formulation according to claim 39, wherein the third vaccine antigen is Hepatitis B virus core antigen (HBcAg).

P3
condid.
